Decreased Expression of Sprouty2 in the Dorsolateral Prefrontal Cortex in Schizophrenia and Bipolar Disorder: a Correlation with BDNF Expression

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 Mar 13

PMID 18335055

Citations 16

Authors

Anilkumar Pillai

Affiliations

Soon will be listed here.

Abstract

Background: Current theories on the pathophysiology of schizophrenia suggest altered brain plasticity such as decreased neural proliferation and migration, delayed myelination, and abnormal synaptic modeling, in the brain of subjects with schizophrenia. Though functional alterations in BDNF, which plays important role in neuroplasticity, are implicated in many abnormalities found in schizophrenia, the regulatory mechanism(s) involved in the abnormal signaling of BDNF in schizophrenia is not clear. The present study investigated whether Sprouty2, a regulator of growth factor signaling, is abnormally expressed in schizophrenia, and is associated with the changes in BDNF mRNA in this disorder. The potential effect of antipsychotic drugs on Sprouty2 expression was tested in adult rats.

Methods And Findings: Sprouty2 and BDNF gene expression were analyzed in dorsolateral prefrontal cortex samples from the Stanley Array Collection. Quantitative real-time PCR analysis of RNA in 100 individuals (35 with schizophrenia, 31 with bipolar disorder, and 34 psychiatrically normal controls) showed significantly decreased expression of Sprouty2 and BDNF in both schizophrenia and bipolar disorder. Moreover, a significant correlation between these two genes existed in control, schizophrenia and bipolar subjects. Long-term treatment with antipsychotic drugs, haloperidol and olanzapine, showed differential effects on both Sprouty2 and BDNF mRNA and protein levels in the frontal cortex of rats.

Conclusion: These findings demonstrating decreased expression of Sprouty2 associated with changes in BDNF, suggest the possibility that these decreases are secondary to treatment rather than to factors that are significant in the disease process of either schizophrenia and/or bipolar disorder. Further exploration of Sprouty2-related signal transduction pathways may be helpful to design novel treatment strategies for these disorders.

Citing Articles

Brain-derived neurotrophic factor (BDNF) changes in rodent models of schizophrenia induced by ketamine: a systematic review.

Motamedi-Manesh A, Asanjan M, Fallah H, Gharibian S, Taghavi A, Poode Z Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976721 DOI: 10.1007/s00210-025-03912-7.

Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Schizophrenia and Bipolar Disorder: A Systematic Review.

Liberona A, Jones N, Zuniga K, Garrido V, Zelada M, Silva H Int J Mol Sci. 2024; 25(20).

PMID: 39456983 PMC: 11508575. DOI: 10.3390/ijms252011204.

SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental Disorders: Current Knowledge and Future Perspectives.

Puranik N, Jung H, Song M Int J Mol Sci. 2024; 25(20).

PMID: 39456824 PMC: 11507918. DOI: 10.3390/ijms252011043.

Gene Expression and Epigenetic Regulation in the Prefrontal Cortex of Schizophrenia.

Bilecki W, Mackowiak M Genes (Basel). 2023; 14(2).

PMID: 36833173 PMC: 9957055. DOI: 10.3390/genes14020243.

Chronic haloperidol administration downregulates select BDNF transcript and protein levels in the dorsolateral prefrontal cortex of rhesus monkeys.

Hemby S, McIntosh S Front Psychiatry. 2023; 14:1054506.

PMID: 36816400 PMC: 9932326. DOI: 10.3389/fpsyt.2023.1054506.

References

Terry Jr A, Hill W, Parikh V, Evans D, Waller J, Mahadik S . Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl). 2002; 164(4):360-8. DOI: 10.1007/s00213-002-1230-z. View

Mueller H, Meador-Woodruff J . NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res. 2004; 71(2-3):361-70. DOI: 10.1016/j.schres.2004.02.016. View

Green W, Patil P, Marsden C, Bennett G, Wigmore P . Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res. 2006; 1070(1):242-5. DOI: 10.1016/j.brainres.2005.11.047. View

Ben-Shachar D, Laifenfeld D . Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol. 2004; 59:273-96. DOI: 10.1016/S0074-7742(04)59011-6. View

Jarskog L, Gilmore J, Glantz L, Gable K, German T, Tong R . Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology. 2006; 32(1):95-102. DOI: 10.1038/sj.npp.1301074. View

Durany N, Michel T, Zochling R, Boissl K, Cruz-Sanchez F, Riederer P . Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 2001; 52(1-2):79-86. DOI: 10.1016/s0920-9964(00)00084-0. View

Rylett R, Williams L . Role of neurotrophins in cholinergic-neurone function in the adult and aged CNS. Trends Neurosci. 1994; 17(11):486-90. DOI: 10.1016/0166-2236(94)90138-4. View

Buckley P, Pillai A, Evans D, Stirewalt E, Mahadik S . Brain derived neurotropic factor in first-episode psychosis. Schizophr Res. 2007; 91(1-3):1-5. PMC: 1933504. DOI: 10.1016/j.schres.2006.12.026. View

Sweatt J . Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004; 14(3):311-7. DOI: 10.1016/j.conb.2004.04.001. View

10.

Kinon B, Lieberman J . Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996; 124(1-2):2-34. DOI: 10.1007/BF02245602. View

11.

Grillo R, Ottoni G, Leke R, Souza D, Portela L, Lara D . Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2006; 41(1-2):31-5. DOI: 10.1016/j.jpsychires.2006.01.005. View

12.

Yang B, Son H, Kim S, Nam J, Choi J, Lee J . Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci. 2004; 58(3):262-7. DOI: 10.1111/j.1440-1819.2004.01229.x. View

13.

De Luca V, Likhodi O, Van Tol H, Kennedy J, Wong A . Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berl). 2005; 183(3):378-82. DOI: 10.1007/s00213-005-0191-4. View

14.

Xing J, Kornhauser J, Xia Z, Thiele E, Greenberg M . Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol. 1998; 18(4):1946-55. PMC: 121424. DOI: 10.1128/MCB.18.4.1946. View

15.

Hashimoto T, Bergen S, Nguyen Q, Xu B, Monteggia L, Pierri J . Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005; 25(2):372-83. PMC: 6725470. DOI: 10.1523/JNEUROSCI.4035-04.2005. View

16.

Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, Koike K . Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett. 2003; 351(2):111-4. DOI: 10.1016/j.neulet.2003.08.004. View

17.

Bymaster F, Hemrick-Luecke S, Perry K, Fuller R . Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl). 1996; 124(1-2):87-94. DOI: 10.1007/BF02245608. View

18.

Gross I, Armant O, Benosman S, de Aguilar J, Freund J, Kedinger M . Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death Differ. 2007; 14(10):1802-12. DOI: 10.1038/sj.cdd.4402188. View

19.

Jockers-Scherubl M, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F . Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett. 2004; 371(1):79-83. DOI: 10.1016/j.neulet.2004.08.045. View

20.

Kyosseva S . The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia. Cerebellum. 2004; 3(2):94-9. DOI: 10.1080/14734220410029164. View